Survival and Economic Impact of Rapid Prostate-Specific Antigen Doubling Time in Patients With Nonmetastatic Castration-Resistant Prostate Cancer.

[1]  A. Jemal,et al.  Cancer statistics for African American/Black People 2022 , 2022, CA: a cancer journal for clinicians.

[2]  R. Ionescu-Ittu,et al.  Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors , 2021, Advances in Therapy.

[3]  K. Aben,et al.  The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population , 2021, Prostate Cancer and Prostatic Diseases.

[4]  W. Lowrance,et al.  Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II. , 2020, The Journal of urology.

[5]  S. Shariat,et al.  Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis , 2020, International Journal of Clinical Oncology.

[6]  T. Tammela,et al.  Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. , 2020, The New England journal of medicine.

[7]  F. Saad,et al.  Apalutamide and Overall Survival in Prostate Cancer. , 2020, European urology.

[8]  S. Freedland,et al.  Predictors of survival, healthcare resource utilization, and healthcare costs in veterans with non-metastatic castration-resistant prostate cancer. , 2020, Urologic oncology.

[9]  F. Saad,et al.  Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.

[10]  K. Tangirala,et al.  A Retrospective Claims Analysis of Advanced Prostate Cancer Costs and Resource Use , 2019, PharmacoEconomics - Open.

[11]  F. Saad,et al.  Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. , 2019, The Lancet. Oncology.

[12]  T. Tammela,et al.  Darolutamide in Nonmetastatic, Castration‐Resistant Prostate Cancer , 2019, The New England journal of medicine.

[13]  W. Oyen,et al.  Managing Nonmetastatic Castration-resistant Prostate Cancer. , 2019, European urology.

[14]  F. Saad,et al.  Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. , 2018, The Lancet. Oncology.

[15]  F. Saad,et al.  Enzalutamide in Men with Nonmetastatic, Castration‐Resistant Prostate Cancer , 2018, The New England journal of medicine.

[16]  F. Saad,et al.  Apalutamide Treatment and Metastasis‐free Survival in Prostate Cancer , 2018, The New England journal of medicine.

[17]  M. Terris,et al.  Thresholds for PSA doubling time in men with non‐metastatic castration‐resistant prostate cancer , 2017, BJU international.

[18]  M. Terris,et al.  Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer , 2015, Prostate Cancer and Prostatic Disease.

[19]  F. Saad,et al.  Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  E. Horwitz,et al.  Prostate-specific antigen doubling time predicts the development of distant metastases for patients who fail 3-dimensional conformal radiotherapy or intensity modulated radiation therapy using the Phoenix definition , 2011 .

[21]  J. Nelson,et al.  Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration‐resistant nonmetastatic prostate cancer , 2011, Cancer.

[22]  M. Terris,et al.  Does PSADT after radical prostatectomy correlate with overall survival?--a report from the SEARCH database group. , 2011, Urology.

[23]  F. Saad,et al.  Guidelines for the management of castrate-resistant prostate cancer , 2010 .

[24]  A. D'Amico,et al.  Prostate Specific Antigen Doubling Time , 2008 .

[25]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  H. Quan,et al.  Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data , 2005, Medical care.

[27]  F. Saad,et al.  Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Ming-Hui Chen,et al.  Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. , 2003, Journal of the National Cancer Institute.

[29]  A W Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.